logo

Akebia Therapeutics, Inc. (AKBA)



Trade AKBA now with
  Date
  Headline
6/29/2020 7:46:11 AM Akebia Announces First Regulatory Approval Of Vadadustat For Treatment Of Anemia Due To Chronic Kidney Disease
6/18/2020 4:02:57 PM Akebia Therapeutics Appoints David Spellman As SVP, CFO And Treasurer
6/10/2020 8:16:44 AM Akebia Therapeutics Announces Data On Different Dosing Regimens Of Ferric Citrate For Iron Deficiency Anemia
6/2/2020 4:34:47 PM Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/18/2020 8:04:31 AM Akebia Therapeutics Announces Collaboration Partner's Submission Of SNDA For Use Of Riona In Japan
5/11/2020 9:18:54 PM Akebia Prices Underwritten Public Offering Of 11 Mln Shares At $12.00/shr
5/5/2020 7:52:48 AM Akebia Announced Positive Top-Line Results From Global Phase 3 Program Of Vadadustat
5/5/2020 7:21:11 AM Akebia Unveils Positive Top-Line Results From Phase 3 Program Of Vadadustat For Anemia Due To Chronic Kidney Disease
4/7/2020 8:13:15 AM Akebia Therapeutics Appoints Myles Wolf To Board
3/15/2020 9:33:14 PM Akebia Therapeutics Asks All Office-based Employees To Work Remotely Due To Coronavirus Outbreak
3/10/2020 7:56:13 AM Akebia Therapeutics Q4 Total Revenue Rises To $69.6 Mln from $59.9 Mln Prior Year
11/12/2019 8:01:16 AM Akebia Therapeutics Q3 Loss Per Share $0.46, Same As Last Year